Author’s response to reviews

Title: Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines.

Authors:

Panagiotis Apostolou (apostolou.panagiotis@rgcc-genlab.com)
Maria Tolouidi (tolouidi.maria@rgcc-genlab.com)
Marina Chatziioannou (chatziioannou.marina@rgcc-genlab.com)
Eleni Ioannou (ioannou.eleni@rgcc-genlab.com)
Dennis R Knocke (dknockke@neriumbiotech.com)
Joe Nester (jnester@neriumbiotech.com)
Dimitrios Komiotis (dkom@bio.uth.gr)
Ioannis Papasotiriou (papasotiriou.ioannis@rgcc-genlab.com)

Version: 2 Date: 11 February 2013

Author’s response to reviews: see over
To:

Christopher Morrey
Executive Editor,

BMC Clinical Pharmacology and Toxicology

Dear Editor,

We would like to resubmit our revised manuscript entitled “Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines” for consideration for publication in the BMC Clinical Pharmacology and Toxicology.

Firstly, we would like to thank the reviewers for their comments. Concerning the comments, we present the changes that have been made.

All the tables and figures have been changed, to interpret the results more clearly. The new figures present the effect of each formulation separately and in combination with each other, both on cell growth (Growth Inhibition), and the effect on mortality (Lethal Concentration). Furthermore are presented results for all types of cancer that were studied.

The discussion was changed and added new data regarding the clinical field. The results were based in MTT assay, which is quite robust. Finally, the densities replaced by concentrations.

All authors have read and approved the revised manuscript. The manuscript has neither been published nor is currently under consideration for publication by any other journal.

We would like to thank you in advance for your consideration and time. Contact details are shown on the title page of the manuscript.

Sincerely,

Dr. Papasotiriou Ioannis, MD
Medical Director of R.G.C.C. Ltd